Shopping Cart
- Remove All
Your shopping cart is currently empty
INE963 demonstrates potent cellular activity against Pf 3D7 (EC50 = 6 nM) and achieves "artemisinin-like" kill kinetics in vitro with a parasite clearance time of <24 h. INE963 is also potent against P. falciparum and P. vivax clinical isolates from Brazil and Uganda with EC50's ranging from 0.01 to 7.0 nM

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $57 | In Stock | |
| 5 mg | $137 | In Stock | |
| 10 mg | $213 | In Stock | |
| 25 mg | $435 | In Stock | |
| 50 mg | $643 | In Stock | |
| 100 mg | $915 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $163 | In Stock |
| Description | INE963 demonstrates potent cellular activity against Pf 3D7 (EC50 = 6 nM) and achieves "artemisinin-like" kill kinetics in vitro with a parasite clearance time of <24 h. INE963 is also potent against P. falciparum and P. vivax clinical isolates from Brazil and Uganda with EC50's ranging from 0.01 to 7.0 nM |
| Targets&IC50 | Pf3D7:6 nM(EC50) |
| In vitro | INE963 is active against >15 drug-resistant Pf cell lines with EC50’s = 0.5–15 nM. The in vitro log parasite reduction ratio for INE963 is >8.0 at 10 × Pf 3D7 EC50 without a lag phase and a parasite clearance time (PCT99.9) of <24 h. The in vitro selectivity of INE963for Plasmodium vs human cells was exemplified by approximately 1000+ fold shifts against multiple human kinase biochemical assays[1]. |
| In vivo | Following four oral doses at 30 mg/kg of INE963, the frontrunner compounds tested showed significant parasitemia reduction (>99.9%) at day 5 compared to untreated control mice. In addition, the animals did not show any signs of recrudescence of parasite at day 60 post-treatment, indicating complete cure at these doses[1]. |
| Molecular Weight | 402.51 |
| Formula | C19H26N6O2S |
| Cas No. | 2640567-43-5 |
| Smiles | COc1nc(ccc1-c1cnc2sc(nn12)N1CCC(O)(CN)CC1)C(C)C |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| In Vivo Formulation | 50% PEG300+50% Saline: 5 mg/mL (12.42 mM) Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.